Preliminary diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation
BACKGROUND: It is recommended to perform multiparametric magnetic resonance imaging (mpMRI) in the follow-up following focal therapy of prostate cancer (PCa). OBJECTIVE: To determine the diagnostic accuracy of mpMRI to detect residual PCa following focal therapy with irreversible electroporation. DESIGN, SETTING, AND PARTICIPANTS: Seventy-six patients with biopsy-proven localized PCa consented for primary irreversible electroporation between February 2013 and March 2016. Final analysis was performed on 50 patients that received follow-up mpMRI at 6 mo, serial prostate-specific antigen (PSA) testing, and transperineal template-mapping biopsies at 12 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outfield regions of interest (ROI) were reported using PI-RADS version 2. A binary outcome (suspicious vs nonsuspicious) was given for the infield ablation zone. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated for different definitions of significant PCa: (1) Gleason >/=4+3 or Gleason >/=3+3 with a maximum cancer core length >/=6mm, (2) Gleason >/=3+4 or Gleason >/=3+3 with a maximum cancer core length >/=4mm, for outfield and infield ROI. Multivariate linear regression analyses evaluated the additional value of nadir PSA. RESULTS AND LIMITATIONS: Sensitivity, specificity, positive predictive values, and negative predictive values of infield ROI was 43%, 86%, 33%, and 90% for definition 1 and 38%, 86%, 33%, and 88% for definition 2, respectively. For outfield ROI this was 33%, 82%, 20%, and 90% for definition 1 and 38%, 86%, 50%, and 80% for definition 2. PSA had no additional value in predicting residual significant PCa. Limitations include retrospective design, single reader, and low incidence of residual PCa. CONCLUSIONS: Our preliminary data suggest that mpMRI can rule out high-volume residual PCa. However, follow-up biopsies should still be performed to determine oncological control. PATIENT SUMMARY: Multiparametric magnetic resonance imaging is able to detect high-volume significant prostate cancer following focal therapy. Prostate biopsies are still required in the follow-up of focal therapy as (low-volume) significant prostate cancer is being missed by multiparametric magnetic resonance imaging.
|Authors||Scheltema, M. J.; Chang, J. I.; van den Bos, W.; Bohm, M.; Delprado, W.; Gielchinsky, I.; de Reijke, T. M.; de la Rosette, J. J.; Siriwardana, A. R.; Shnier, R.; Stricker, P. D.|
|Publisher Name||European Urology Focus|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/29102671|